US 12,109,264 B2
Motile sperm domain containing protein 2 and inflammation
Itzhak Mendel, Rehovot (IL); Oshrat Propheta-Meiran, Petah Tikva (IL); Yaniv Salem, Kyriat Ono (IL); Anat Shoham, Hod Hasharon (IL); and Eyal Breitbart, Hashmonaim (IL)
Assigned to ImmuneWalk Therapeutics, Inc., Pearl River, NY (US)
Filed by ImmuneWalk Therapeutics, Inc., Pearl River, NY (US)
Filed on Sep. 14, 2020, as Appl. No. 17/019,893.
Application 17/019,893 is a continuation of application No. 15/747,918, abandoned, previously published as PCT/IB2016/054582, filed on Jul. 29, 2016.
Claims priority of provisional application 62/199,609, filed on Jul. 31, 2015.
Prior Publication US 2021/0077622 A1, Mar. 18, 2021
Int. Cl. C12N 15/11 (2006.01); A61K 31/7105 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 29/00 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01); A61K 48/00 (2006.01); C12N 15/113 (2010.01)
CPC A61K 39/3955 (2013.01) [A61K 31/7105 (2013.01); A61K 39/0008 (2013.01); A61K 39/001102 (2018.08); A61P 29/00 (2018.01); A61P 37/06 (2018.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); A61K 48/0016 (2013.01); C12N 15/113 (2013.01); C12N 2310/531 (2013.01); Y02A 50/30 (2018.01)] 20 Claims
 
1. A method of treating a chronic inflammatory disease or disorder in a subject, comprising administering to the subject an inhibitor of MOSPD2, wherein the inhibitor is an RNA silencing agent, and
wherein the chronic inflammatory disease or disorder is rheumatoid arthritis, systemic lupus erythematosus, scleroderma, mixed connective tissue disease, polyarteritis nodosa, polymyositis/dermatomyositis, Sjogren's syndrome, Behcet's disease, multiple sclerosis, autoimmune diabetes, Hashimoto's disease, psoriasis, primary myxedema, pernicious anemia, myasthenia gravis, chronic active hepatitis, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, uveitis, vasculitides, or heparin induced thrombocytopenia.